TAK-659, a dual SYK/FLT3 inhibitor, leads to complete and sustained tumor regression and immune memory against tumor cells upon combination with anti-PD-1 agent. (December 2016) - Kannan, K.; Riley, J.; Zhang, M.; Farrell, P.; Bailey, B.; Creson, J.; Fujitani, Y.; Yu, J.; Huck, J.